Overview

Tissue Kallikrein Preventing the Restenosis After Stenting of Symptomatic MCA Atherosclerotic Stenosis

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The study aims to determine whether tissue kallikrein (TK) is efficacy for preventing the long-term in-stent restenosis (ISR) after stenting of symptomatic atherosclerotic stenosis of the middle cerebral artery (MCA) M1 segment
Phase:
Phase 2
Details
Lead Sponsor:
Jinling Hospital, China
Treatments:
Kallikreins